WHAT IS CLAIMED IS:

1. A method of administering to a subject in need thereof an effective amount of a cisplatin active agent, said method comprising:

administering to said host said effective amount of a cisplatin active agent in conjunction with an amount of a cisplatin toxicity reducing agent effective to reduce toxicity of said cisplatin active agent.

2. The method according to Claim 1, wherein said cisplatin active agent and cisplatin toxicity reducing agent are administered at the same time.

3. The method according to Claim 2, wherein said cisplatin active agent and cisplatin toxicity reducing agent are administered as separate formulations.

4. The method according to Claim 2, wherein said cisplatin active agent and cisplatin toxicity reducing agent are administered in a single formulation.

5. The method according to Claim 1, wherein said cisplatin active agent and said cisplatin toxicity reducing agent are administered sequentially.

6. The method according to Claim 5, wherein said cisplatin active agent is administered prior to said cisplatin toxicity reducing agent.

7. The method according to Claim 5, wherein said cisplatin active agent is administered after said cisplatin toxicity reducing agent.

8. The method according to Claim 1, wherein the amount of said cisplatin toxicity reducing agent is not more than about the amount of said cisplatin active agent.

9. The method according to Claim 1, wherein said cisplatin active agent is cisplatin.

10. The method according to Claim 1, wherein said cisplatin toxicity reducing agent is a small organic compound.

11. The method according to Claim 10, wherein said small organic compound is chosen from TK-5175, TK-5145, TK-295, TK-516, TK-363, TK-204, TK-523 and TK-211.

12. A pharmaceutical composition comprising an effective amount of both a cisplatin active agent and an cisplatin toxicity reducing agent in a pharmaceutically acceptable vehicle.

13. The pharmaceutical composition according to Claim 12, wherein the amount of said cisplatin toxicity reducing agent is not more than about the amount of said cisplatin active agent.

14. The pharmaceutical composition according to Claim 12, wherein said cisplatin active agent is cisplatin.

15. The pharmaceutical composition according to Claim 12, wherein said cisplatin toxicity reducing agent is a small organic compound.

16. The pharmaceutical composition according to Claim 15, wherein said small organic compound is chosen from TK-5175, TK-5145, TK-295, TK-516, TK-363, TK-204, TK-523 and TK-211.

17. A method of treating a host suffering from a cellular proliferative disease condition, said method comprising:

administering to said host said effective amount of a cisplatin active agent in conjunction with an amount of a cisplatin toxicity reducing agent effective to reduce toxicity of said cisplatin active agent so that said host is treated for said cellular proliferative disease condition.

18. The method according to Claim 17, wherein said cisplatin active agent and cisplatin toxicity reducing agent are administered at the same time.

19. The method according to Claim 18, wherein said cisplatin active agent and cisplatin toxicity reducing agent are administered as separate formulations.

20. The method according to Claim 18, wherein said cisplatin active agent and cisplatin toxicity reducing agent are administered in a single formulation.

21. The method according to Claim 17, wherein said cisplatin active agent and said cisplatin toxicity reducing agent are administered sequentially.

22. The method according to Claim 21, wherein said cisplatin active agent is administered prior to said cisplatin toxicity reducing agent.

23. The method according to Claim 21, wherein said cisplatin active agent is administered after said cisplatin toxicity reducing agent.

24. The method according to Claim 17, wherein the amount of said cisplatin toxicity reducing agent is not more than about the amount of said cisplatin active agent.

25. The method according to Claim 17, wherein said cisplatin active agent is cisplatin.

26. The method according to Claim 17, wherein said cisplatin toxicity reducing agent is a small organic compound.

27. The method according to Claim 26, wherein said small organic compound is chosen from TK-5175, TK-5145, TK-295, TK-516, TK-363, TK-204, TK-523 and TK-211.

28. A kit for use in treating a host suffering from a cellular proliferative disease condition, said kit comprising:

(a) a cisplatin active agent; and

(b) a cisplatin toxicity reducing agent.

29. The kit according to Claim 28, wherein said cisplatin active agent and cisplatin toxicity reducing agent are present as separate compositions.

30. The kit according to Claim 28, wherein said cisplatin active agent and cisplatin toxicity reducing agent are present in the same composition.